ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
<p>Abstract</p> <p>Background</p> <p>Acquired radioresistance of cancer cells remains a fundamental barrier to attaining the maximal efficacy of radiotherapy for the treatment of breast cancer. Anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, play an important role in...
Main Authors: | Li Ji-Yu, Li Yu-Yang, Jin Wei, Yang Qing, Shao Zhi-Ming, Tian Xing-Song |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://www.jeccr.com/content/31/1/102 |
Similar Items
-
Inhibition des protéines anti-apoptotiques de la famille Bcl-2 par l'ABT-737 : intérêt pour le traitement des cancers des voies aérodigestives supérieures
by: Gilormini, Marion
Published: (2015) -
ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
by: Ricardo Parrondo, et al.
Published: (2013-09-01) -
ΔN-Bcl-xL, a therapeutic target for neuroprotection
by: Han-A Park, et al.
Published: (2017-01-01) -
BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
by: María Josefina Quezada, et al.
Published: (2021-12-01) -
Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
by: Tareq Saleh, et al.
Published: (2020-10-01)